Barclays PLC Increases Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP)

Barclays PLC raised its holdings in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) by 1,124.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 41,522 shares of the company’s stock after buying an additional 38,132 shares during the period. Barclays PLC owned about 0.12% of ArriVent BioPharma worth $976,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. State Street Corp boosted its position in shares of ArriVent BioPharma by 210.4% during the third quarter. State Street Corp now owns 476,809 shares of the company’s stock valued at $11,205,000 after buying an additional 323,186 shares during the period. Suvretta Capital Management LLC boosted its position in shares of ArriVent BioPharma by 7.7% during the third quarter. Suvretta Capital Management LLC now owns 1,845,162 shares of the company’s stock valued at $43,361,000 after buying an additional 132,459 shares during the period. MetLife Investment Management LLC raised its stake in shares of ArriVent BioPharma by 168.9% during the third quarter. MetLife Investment Management LLC now owns 16,350 shares of the company’s stock valued at $384,000 after acquiring an additional 10,269 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of ArriVent BioPharma by 32.6% during the third quarter. BNP Paribas Financial Markets now owns 21,965 shares of the company’s stock valued at $516,000 after acquiring an additional 5,397 shares in the last quarter. Finally, FMR LLC raised its stake in shares of ArriVent BioPharma by 8.7% during the third quarter. FMR LLC now owns 2,119,695 shares of the company’s stock valued at $49,813,000 after acquiring an additional 169,514 shares in the last quarter. Hedge funds and other institutional investors own 9.48% of the company’s stock.

ArriVent BioPharma Stock Down 1.1 %

Shares of AVBP stock opened at $26.95 on Tuesday. The business’s fifty day simple moving average is $29.14 and its 200-day simple moving average is $25.01. ArriVent BioPharma, Inc. has a 12-month low of $14.35 and a 12-month high of $36.37.

Analysts Set New Price Targets

AVBP has been the subject of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price target on shares of ArriVent BioPharma in a research note on Friday, November 15th. Citigroup lifted their price target on shares of ArriVent BioPharma from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Oppenheimer reaffirmed an “outperform” rating and set a $39.00 price target (up previously from $35.00) on shares of ArriVent BioPharma in a research note on Tuesday, September 10th. Finally, The Goldman Sachs Group lifted their price target on shares of ArriVent BioPharma from $28.00 to $38.00 and gave the company a “buy” rating in a research note on Tuesday, September 10th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $36.80.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.